Extracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2016Author
Uygun, VedatDaloğlu, Hayriye
Irmak Öztürkmen, Seda
Döşemeci, Levent
Karasu, Gülsün
Hazar, Volkan
Yeşilipek, Akif
Metadata
Show full item recordCitation
Uygun, V., Daloğlu, H., Irmak Öztürkmen, S., Döşemeci, L., Karasu, G., Hazar, V. ... Yeşilipek, A. (2016). Extracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis. Transfusion, 56(12), 3081-3085. https://dx.doi.org/10.1111/trf.13821Abstract
BACKGROUNDMyasthenia gravis (MG) is a neuromuscular disorder characterized by an autoimmune defect in the neuromuscular junction. In most patients, the autoimmune attack is mediated by antibodies against the acetylcholine receptor (AChR) on the postsynaptic membrane. Deficient immunoregulation, including regulatory T cells, is consistently observed. Extracorporeal photopheresis (ECP) leads to the induction of regulatory T cells that mediate immunologic tolerance in autoimmune diseases; however, the data regarding MG are very limited. CASE REPORTHere, we report a patient who, during ongoing ECP therapy for his severe, refractory, chronic graft-versus-host disease (cGVHD), developed MG, although he responded very well to ECP, as indicated by the lowering of his chronic cGVHD severity grade to moderate. RESULTSDespite receiving ECP, our patient developed MG, which was resistant to treatment and required intensive care unit support. CONCLUSIONSClose surveillance is required when ECP is planned as one of the treatment alternatives in myasthenia gravis that develop in cGVHD.
WoS Q Kategorisi
Q3xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q1Source
TransfusionVolume
56Issue
12Collections
- Makale Koleksiyonu [3642]
- PubMed İndeksli Yayınlar Koleksiyonu [4039]
- Scopus İndeksli Yayınlar Koleksiyonu [6271]
- WoS İndeksli Yayınlar Koleksiyonu [6416]